Corcept Therapeutics (CORT) Assets Average (2011 - 2026)

Corcept Therapeutics has disclosed Assets Average across 16 years of filings, most recently posting $825.8 million for Q1 2026.

• Assets Average for Q1 2026 came in at $825.8 million, down 2.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $825.8 million (down 2.1% YoY), and the FY2025 annual result was $838.6 million, up 14.71% from the prior year.
• Assets Average came in at $825.8 million for Q1 2026 at Corcept Therapeutics, down from $830.1 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $843.5 million in Q1 2025 to a low of $445.9 million in Q1 2022.
• The 5-year median for Assets Average is $638.7 million (2024), against an average of $668.4 million.
• Across the five-year window, Assets Average fell 20.66% in 2022 and jumped 34.69% in 2023, its largest moves.
• Corcept Therapeutics' Assets Average stood at $558.3 million in 2022, then climbed by 8.85% to $607.8 million in 2023, then soared by 33.67% to $812.4 million in 2024, then advanced by 2.18% to $830.1 million in 2025, then slipped by 0.53% to $825.8 million in 2026.
• The last three Assets Average figures came in at $825.8 million (Q1 2026), $830.1 million (Q4 2025), and $812.7 million (Q3 2025), per Business Quant data.